Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AstraZeneca

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

The Economic Times

First-in-Class Drug Targeting Treatment-Resistant High Blood Pressure Wins FDA Approval — and Works Like No Existing Drug

FDA approved baxdrostat (Baxfendy) on May 18, 2026 as the first-ever oral aldosterone synthase inhibitor for uncontrolled and resistant hypertension. BaxHTN Phase 3 (NEJM 2025): 8.7–9.8 mmHg additional systolic blood pressure reduction added to background therapy. Here is the full story.

Medical Daily

Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected?

The vital medicine, made by AstraZeneca, will not be available from November, possibly leaving thousands of women without treatment

The Guardian - AU

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca daily pill shows promising weight loss results in trial

IN FULL

The Independent UK

New daily weight loss pill helps people shed 10 per cent of body weight

The pill doesn’t have the fasting requirements of many other weight loss drugs

The Independent UK

India a major growth market for Celonis, says senior exec

The Germany-based company said it already serves 260 global capability centres (GCCs) in India, counting companies such as Mercedes-Benz, Hitachi Energy and AstraZeneca as its clients, and sees a larger opportunity ahead as enterprises try to connect AI systems with operational data spread across departments and software systems.

The Economic Times

NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History

NEW YORK, June 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on June 5thInvestors are reacting to the May jobs…

AAP

Read news from The Economist, FT, and more,
with one subscription

Low-dose Zoladex won’t be available in Australia from November. What might that mean for you?

The drug goserelin – commonly known as Zoladex – has been a quietly crucial medicine in Australia for decades.

The Conversation

A Key Endometriosis & Breast Cancer Drug Is Being Pulled From Australia: ‘Deeply Concerned’

AstraZeneca will discontinue the Zoladex 3.6mg implant in Australia from November 2026, affecting people with breast cancer and endometriosis.

Pedestrian.tv

Women dying of breast cancer as life-extending drug remains blocked in England

A campaign is calling for Enhertu to be made available on the NHS.

Evening Standard

Compugen Q1 Earnings Call Highlights

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the

MarketBeat

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

MarketBeat

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing to access, international launches and prescriber expansion as key drivers for the rest of the year

MarketBeat

Innate Pharma Q1 Earnings Call Highlights

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

White House Says Trump's Drugmaker Deals Could Save U.S. Economy $529 Billion Over 10 Years

The White House said on Tuesday that agreements with major drugmakers could save the U.S. economy $529 billion over the next decade.

MarketBeat

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

Fortune

How AstraZeneca's 17,000 AI-certified employees are helping it reach a 'stretch goal' of $80 billion in revenue

CFO Aradhana Sarin breaks down the building blocks behind the revenue target and reflects on a strong Q1.

Evening Standard

FTSE 100 closes lower as drugs firms GSK and AstraZeneca struggle

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Pharmaceutical giant to invest £300m in Britain after UK-US deal

IN FULL

The Independent UK

AstraZeneca to inject £300 million into UK in surprise U-turn

AstraZeneca chief executive Pascal Soriot has thanked the Government ‘for their efforts to improve access for patients’

The Guardian - UK

AstraZeneca makes surprise U-turn with £300m pharma investment in UK

Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer

Evening Standard

Shot in the arm for GSK and AstraZeneca from cancer drug sales

The blue chip drug makers saw first quarter earnings beat market expectations.

Evening Standard

Blue chips close lower amid US-Iran stalemate

For the week, the FTSE 100 fell 2.7%, the FTSE 250 also declined 2.7% and the AIM All-Share dipped 1.7%.

The Independent UK

‘My husband had the Covid-19 vaccine – 11 days later he was dead’

Stephen Ward developed a blood clot after a dose of AstraZeneca

The Guardian - UK

GSK reports promising early results in ovarian and womb cancer drug trial

Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.